These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26029716)

  • 1. Preclinical safety and efficacy studies with an affinity-enhanced epithelial junction opener and PEGylated liposomal doxorubicin.
    Richter M; Yumul R; Wang H; Saydaminova K; Ho M; May D; Baldessari A; Gough M; Drescher C; Urban N; Roffler S; Zubieta C; Carter D; Fender P; Lieber A
    Mol Ther Methods Clin Dev; 2015; 2():15005. PubMed ID: 26029716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coadministration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs.
    Beyer I; Cao H; Persson J; Song H; Richter M; Feng Q; Yumul R; van Rensburg R; Li Z; Berenson R; Carter D; Roffler S; Drescher C; Lieber A
    Clin Cancer Res; 2012 Jun; 18(12):3340-51. PubMed ID: 22535153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming physical barriers in cancer therapy.
    Beyer I; van Rensburg R; Lieber A
    Tissue Barriers; 2013 Jan; 1(1):e23647. PubMed ID: 24665377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer.
    Beyer I; van Rensburg R; Strauss R; Li Z; Wang H; Persson J; Yumul R; Feng Q; Song H; Bartek J; Fender P; Lieber A
    Cancer Res; 2011 Nov; 71(22):7080-90. PubMed ID: 21990319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Junction opener protein increases nanoparticle accumulation in solid tumors.
    Wang CE; Yumul RC; Lin J; Cheng Y; Lieber A; Pun SH
    J Control Release; 2018 Feb; 272():9-16. PubMed ID: 29305923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models.
    Yumul R; Richter M; Lu ZZ; Saydaminova K; Wang H; Wang CH; Carter D; Lieber A
    Hum Gene Ther; 2016 Apr; 27(4):325-37. PubMed ID: 26993072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational development of a tumor junction opening technology.
    Kim J; Li C; Wang H; Kaviraj S; Singh S; Savergave L; Raghuwanshi A; Gil S; Germond A; Baldessari A; Chen B; Roffler S; Fender P; Drescher C; Carter D; Lieber A
    Sci Rep; 2022 May; 12(1):7753. PubMed ID: 35562182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy.
    Gabizon AA
    Cancer Invest; 2001; 19(4):424-36. PubMed ID: 11405181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies.
    Vail DM; Amantea MA; Colbern GT; Martin FJ; Hilger RA; Working PK
    Semin Oncol; 2004 Dec; 31(6 Suppl 13):16-35. PubMed ID: 15717736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer.
    Prado CM; Baracos VE; Xiao J; Birdsell L; Stuyckens K; Park YC; Parekh T; Sawyer MB
    Appl Physiol Nutr Metab; 2014 Jun; 39(6):693-8. PubMed ID: 24869973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of combined PEGylated liposomal doxorubicin and radiofrequency ablation: Comparing single and combined therapy in young and old mice.
    Andriyanov AV; Portnoy E; Koren E; Inesa S; Eyal S; Goldberg SN; Barenholz Y
    J Control Release; 2017 Jul; 257():2-9. PubMed ID: 28215670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.
    Gabizon A; Tzemach D; Mak L; Bronstein M; Horowitz AT
    J Drug Target; 2002 Nov; 10(7):539-48. PubMed ID: 12683721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and toxicity profile of pegylated liposomal doxorubicin in patients with advanced ovarian cancer.
    Mayer C; Brucker J; Schuetz F; Domschke C; Bechstein S; Heil J; Golatta M; Wallwiener M; Sohn C; Schneeweiss A; Rom J
    Arch Gynecol Obstet; 2016 Jul; 294(1):123-9. PubMed ID: 26498757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxebo (doxorubicin-free Doxil-like liposomes) is safe to use as a pre-treatment to prevent infusion reactions to PEGylated nanodrugs.
    Bavli Y; Winkler I; Chen BM; Roffler S; Cohen R; Szebeni J; Barenholz Y
    J Control Release; 2019 Jul; 306():138-148. PubMed ID: 31176656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin.
    Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Kikuchi H; Ishihara H
    Int J Pharm; 2014 Dec; 476(1-2):205-12. PubMed ID: 25280884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of low-dose tumor necrosis factor-alpha to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats.
    Hoving S; Seynhaeve AL; van Tiel ST; Eggermont AM; ten Hagen TL
    Anticancer Drugs; 2005 Jul; 16(6):667-74. PubMed ID: 15930896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
    Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
    Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
    Arabi L; Badiee A; Mosaffa F; Jaafari MR
    J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
    Andreopoulou E; Gaiotti D; Kim E; Downey A; Mirchandani D; Hamilton A; Jacobs A; Curtin J; Muggia F
    Ann Oncol; 2007 Apr; 18(4):716-21. PubMed ID: 17301073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.